Drug Trial Radar · NCT02389036
Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients
Last checked: Nov 19, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20,010
Actual
Start
May 1, 2017
Primary completion
Apr 26, 2023
Study completion Apr 26, 2023
Sponsor
- Lead sponsor
- The George InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Imperial College London; Sunnybrook Health Sciences Centre
- First posted
- Mar 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Introduction- Hospital acquired infections (HAI) are a major cause of morbidity and mortality and increase health care costs. Critically ill patients are particularly susceptible to these infections and have an even higher mortality. One intervention that has gained much interest in the medical literature for reducing infection rates and deaths from HAIs is selective decontamination of the digestive tract (SDD). SDD involves the application of antibiotic paste to the mouth, throat, stomach and a short course of intravenous antibiotics. The evidence supporting the use of SDD for saving lives and preventing infections is actually quite strong. However, health care professionals in many parts of the world have refrained from using SDD due to fears of the effects of overuse of antibiotics on the frequency of infections with resistant bacteria such as multi-resistant Gram negative organisms, MRSA and Clostridium difficile. SuDDICU is a cross-over, cluster randomised trial comparing the effect of using selective decontamination of the digestive tract (SDD) plus standard care, to standard care alone on hospital mortality in patients receiving mechanical ventilation in the intensive care unit (ICU). Secondary outcomes include an ecological assessment and a long-term health economic analysis.
Conditions
- Critical Illness
- Sepsis
- Septic Shock
- Ventilator Associated Pneumonia
Interventions
SDD Oral PasteDrug
A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
SDD Gastric SuspensionDrug
2\. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
Intravenous AntibioticDrug
A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospital MortalityTime frame: Hospital discharge [up to Day 90 after randomization]
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
The George Institute for Global Health
Sydney, New South Wales, Australia
Sunnybrook Health Sciences Centre
Toronto, Canada
Imperial College London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.